News stories about Cara Therapeutics (NASDAQ:CARA) have trended somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cara Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 48.0614564965077 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Cramer’s lightning round: With so many great bank stocks, stay away from Wells Fargo (finance.yahoo.com)
- Cramer's lightning round: With so many great bank stocks,… (finance.yahoo.com)
- Risky factor of Cara Therapeutics, Inc. (CARA) is observed at 2.94 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Why this stock is considered to be Oversold? Cara Therapeutics, Inc. (CARA) – Nasdaq Chronicle (nasdaqchronicle.com)
- Cara Therapeutics (CARA) Given a $22.00 Price Target at HC Wainwright (americanbankingnews.com)
CARA stock traded up $0.10 during midday trading on Wednesday, reaching $11.87. 94,663 shares of the company’s stock were exchanged, compared to its average volume of 1,085,226. Cara Therapeutics has a 12 month low of $11.11 and a 12 month high of $28.50. The company has a market cap of $393.59, a PE ratio of -6.19 and a beta of 2.92.
Several equities analysts have recently weighed in on CARA shares. Janney Montgomery Scott upgraded shares of Cara Therapeutics from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $27.00 to $21.00 in a research note on Monday, February 12th. Stifel Nicolaus reiterated a “buy” rating and issued a $17.00 price objective on shares of Cara Therapeutics in a research note on Wednesday, January 3rd. Seaport Global Securities started coverage on shares of Cara Therapeutics in a research note on Friday, January 19th. They issued a “buy” rating and a $27.00 price objective on the stock. ValuEngine cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Cara Therapeutics currently has a consensus rating of “Buy” and an average target price of $24.59.
In other news, SVP Frederique Ph.D. Menzaghi sold 15,000 shares of Cara Therapeutics stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the sale, the senior vice president now owns 122,000 shares in the company, valued at $1,830,000. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Derek T. Chalmers sold 5,400 shares of Cara Therapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.00, for a total transaction of $81,000.00. Following the sale, the chief executive officer now owns 1,071,392 shares in the company, valued at approximately $16,070,880. The disclosure for this sale can be found here. In the last quarter, insiders have sold 35,900 shares of company stock worth $538,560. Company insiders own 7.50% of the company’s stock.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.